knowledge -WSS

knowledge

author：entertainment 2025-09-29 18:16:33 - browse：93786

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： After a drawn out lobbying fight, ARPA

Wikipedia

WSS

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Why do women spend more than men on medical expenses?

Sudafed saga points to U.S. issues with evaluating older drugs

Decentralized clinical trials need collaboration to achieve wider use

Paxlovid should be available without a positive Covid test

Why do women spend more than men on medical expenses?

hotspot

knowledge

entertainment

Walensky prepares to leave CDC — and Congress — behind

How one patient went off dialysis — and others can too

Cancer drug shortages should be causing more outrage

Decentralized clinical trials need collaboration to achieve wider use

Peter Hotez and the public health issue of online harassment

Researchers use wearables data and AI to predict preterm birth risk

In age of alternative facts, a scholarly course on calling out crap

FDA advisers vote against ALS treatment from BrainStorm

What does generative AI mean for health care? We asked experts

Congress: Prevent baby formula shortages by passing a new bill

focus

Listen: Who gets the credit for GLP

Did you have Obamacare on your GOP debate bingo card?

Health tech startups drop sharply from 2021 highs

Clinicians often fail to acknowledge the pain caused by long Covid

Listen: Who gets the credit for GLP

Lawsuit challenges CMS nursing home minimum staffing rule

hotspot

Wikipedia

Wikipedia

explore